CoChat
Sign Up
Cited by 117Nitric Oxide and Endothelin EffectsBlood Coagulation and Thrombosis MechanismsAdvanced Glycation End Products research

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress

El-Daly, Mahmoud, Pulakazhi Venu, Vivek Krishna, Saifeddine, Mahmoud, Mihara, Koichiro, Kang, Sean, Fedak, Paul W.M., Alston, Laurie A., Hirota, Simon A., Ding, Hong, Triggle, Chris R., Hollenberg, Morley D.·2018·Vascular Pharmacology
DOI 10.1016/j.vph.2018.06.006
Open this paper in CoChat — free account

Abstract

Hyperglycaemia is a major contributor to diabetic cardiovascular disease with hyperglycaemia-induced endothelial dysfunction recognized as the initiating cause. Coagulation pathway-regulated proteinase-activated receptors (PARs) that can regulate vascular tone in vivo cause eNOS-mediated endothelium-dependent vasodilation; but, the impact of hyperglycaemia on this vasodilatory action of PAR stimulation and the signalling pathways involved are unknown. We hypothesized that vascular sodium-glucose co-transporter 2 activity and hyperglycaemia-induced oxidative stress involving Src-kinase, EGF receptor-kinase, Rho-kinase and protein-kinase-C biochemical signalling pathways would compromise PAR2-mediated endothelium-dependent vasodilation. Using an organ culture approach, wherein murine aorta rings were maintained for 24 h at hyperglycaemic 25 mM versus euglycaemic 10 mM glucose, we observed severely blunted acetylcholine/muscarinic and PAR2-mediated endothelial eNOS/NO-dependent vasodilation. PEG-catalase, superoxide-dismutase, and NADPH-oxidase inhibition (VAS2870) and either SGLT2-inhibition (canagliflozin/dapagliflozin/empagliflozin) or antioxidant gene induction (sulforaphane), prevented the hyperglycaemia-induced impairment of PAR2-mediated vasodilation. Similarly, inhibition of Src-kinase, EGF receptor-kinase, protein kinase-C and Rho-kinase also preserved PAR2-mediated vasodilation in tissues cultured under hyperglycaemic conditions. Thus, intracellular hyperglycaemia, that can be prevented with an inhibitor of the SGLT2 cotransporter that was identified in the vascular tissue and tissue-derived cultured endothelial cells by qPCR, western blot and immunohistochemistry, leads to oxidative stress that compromises PAR2-mediated NOS-dependent vasodilation by an NAPDH oxidase/reactive-oxygen-species-triggered signalling pathway involving EGFR/Src/Rho-kinase and PKC. The data point to novel antioxidant therapeutic strategies including use of an SGLT2 inhibitor and sulforaphane to mitigate hyperglycaemia-induced endothelial dysfunction.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.vph.2018.06.006

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Triggle, 2008, The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely topics in medicine, Cardiovasc. Dis., 12

Cited by

Sorted by citations

See all 117

Related

See all

Metadata

Authors
El-Daly, M., Pulakazhi Venu, V. K., Saifeddine, M., Mihara, K., Kang, S., Fedak, P. W. M., Alston, L. A., Hirota, S. A., Ding, H., Triggle, C. R., & Hollenberg, M. D.
Affiliations
  • University of Calgary (CA)
  • Weill Cornell Medical College in Qatar (QA)
Corresponding author
Hollenberg, Morley D.
ORCID
Venue
Vascular Pharmacology
Publisher
Elsevier BV
Published
2018-10
Volume
109
Pages
56-71
ISSN
1537-1891 (ISSN-L)
DOI
10.1016/j.vph.2018.06.006
OpenAlex
W2808400246
Cited by
117
References
78
Citations by year
2026: 5 · 2025: 12 · 2024: 11 · 2023: 14 · 2022: 16 · 2021: 26 · 2020: 15 · 2019: 14 · 2018: 3
FWCI
9.90
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vascular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Canadian Institutes of Health Research
  • Qatar Foundation National Priorities Research Program (NPRP: 08165-3-054), 4-910-3-244)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
hyperglycemia, protease-activated receptor 2, endothelium-dependent vasodilation, endothelial dysfunction, SGLT2, SGLT2 inhibitors, oxidative stress, NADPH oxidase, reactive oxygen species, Src kinase, EGF receptor, Rho kinase, protein kinase C, sulforaphane, antioxidant therapy, diabetic cardiovascular disease, aortic endothelium
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Animals, Antioxidants, Aorta, Dose-Response Relationship, Drug, Endothelium, Vascular, Hyperglycemia, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Mitochondria, Nitric Oxide, Organ Culture Techniques, Protein Kinase C, Vasodilation, Signal Transduction, Oxidative Stress, src-Family Kinases, Endothelial Cells, Receptor, PAR-2, Sodium-Glucose Transporter 2, Nitric Oxide Synthase Type II, rho-Associated Kinases, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review